We can’t show the full text here under this license. Use the link below to read it at the source.
Semaglutide for the treatment of overweight and obesity: A review
Semaglutide as a treatment for overweight and obesity
AI simplified
Abstract
Semaglutide 2.4 mg is associated with mean weight losses of 14.9%-17.4% among individuals with overweight or obesity without type 2 diabetes over 68 weeks.
- 69%-79% of participants achieved at least 10% weight loss with semaglutide 2.4 mg compared to 12%-27% with placebo.
- 51%-64% of participants achieved at least 15% weight loss with semaglutide 2.4 mg, while 5%-13% achieved this with placebo.
- In individuals with overweight or obesity and type 2 diabetes, mean weight loss was -9.6% with semaglutide 2.4 mg versus -3.4% with placebo over 68 weeks.
- Improvements in cardiometabolic risk factors, such as high blood pressure and atherogenic lipids, were observed with semaglutide 2.4 mg.
- The safety profile of semaglutide 2.4 mg was consistent across trials, primarily involving gastrointestinal adverse events.
AI simplified
Key numbers
14.9%-17.4%
Mean Weight Loss
Weight loss percentage from baseline to week 68 in participants without diabetes.
69%-79%
Participants Achieving ≥10% Weight Loss
Proportion of participants achieving this milestone with semaglutide 2.4 mg vs. placebo.